
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp PLC demonstrates a promising outlook due to its clinical pipeline addressing significant unmet medical needs, including amyloid diseases, neurodegenerative disorders, and inflammatory conditions. The company has guided expectations for generating up to $105 million in aggregate milestone payments by 2026 from collaborations with partners Novo Nordisk and Bristol-Myers Squibb, suggesting strong financial potential. Additionally, while there are concerns regarding ARIA incidence related to specific treatments, other therapeutic candidates, such as PRX012, have shown favorable tolerability and reduced amyloid levels, enhancing the overall attractiveness of the company’s product portfolio.
Bears say
Prothena Corp PLC faces a challenging financial outlook due to continuous net losses expected until product approval and commercialization, coupled with the financial necessity of raising additional capital, which could dilute shareholder value. The company's clinical pipeline, while promising, is further complicated by elevated ARIA levels observed in its PRX012 candidate and the potential for changing regulatory dynamics that could impose new barriers to drug approval. Additionally, uncertainties surrounding the efficacy of its investigational therapeutics and the associated regulatory risks contribute to an overall negative sentiment regarding the company’s future financial performance.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares